20 analysts have shared their evaluations of Edwards Lifesciences EW during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 4 | 12 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 3 | 3 | 0 | 0 |
| 2M Ago | 0 | 0 | 5 | 0 | 0 |
| 3M Ago | 1 | 1 | 4 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $75.7, a high estimate of $90.00, and a low estimate of $63.00. Experiencing a 0.67% decline, the current average is now lower than the previous average price target of $76.21.
Decoding Analyst Ratings: A Detailed Look
The standing of Edwards Lifesciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Travis Steed | B of A Securities | Raises | Buy | $90.00 | $82.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $83.00 | $81.00 |
| David Roman | Goldman Sachs | Raises | Buy | $90.00 | $81.00 |
| Richard Newitter | Truist Securities | Raises | Hold | $78.00 | $70.00 |
| Rick Wise | Stifel | Raises | Hold | $75.00 | $70.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $85.00 | $80.00 |
| William Plovanic | Canaccord Genuity | Raises | Hold | $68.00 | $63.00 |
| Matt Miksic | Barclays | Raises | Overweight | $88.00 | $85.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $80.00 | $75.00 |
| William Plovanic | Canaccord Genuity | Lowers | Hold | $63.00 | $66.00 |
| Robbie Marcus | JP Morgan | Raises | Neutral | $78.00 | $72.00 |
| Adam Maeder | Piper Sandler | Lowers | Neutral | $70.00 | $73.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $70.00 | $71.00 |
| David Rescott | Baird | Lowers | Neutral | $68.00 | $73.00 |
| Patrick Wood | Morgan Stanley | Announces | Equal-Weight | $70.00 | - |
| Shagun Singh | RBC Capital | Lowers | Outperform | $75.00 | $85.00 |
| William Plovanic | Canaccord Genuity | Lowers | Hold | $66.00 | $77.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $70.00 | $76.00 |
| Joanne Wuensch | Citigroup | Lowers | Buy | $77.00 | $83.00 |
| Matthew Taylor | Jefferies | Lowers | Hold | $70.00 | $85.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Edwards Lifesciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Edwards Lifesciences compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
For valuable insights into Edwards Lifesciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
About Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Edwards Lifesciences's Financial Performance
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Edwards Lifesciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.93% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Edwards Lifesciences's net margin excels beyond industry benchmarks, reaching 226.73%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Edwards Lifesciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 36.16% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Edwards Lifesciences's ROA stands out, surpassing industry averages. With an impressive ROA of 26.62%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.07.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
